CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, announced today the issuance by the US Patent Office of a patent that covers the in situ imaging of the spatial transcriptome. U.S. Patent No. 11,959,075 is for robust multiplex imaging of RNA and its spatial organization in a sample. "This latest patent relates to our MERFISH technology and enables groundbreaking advancements in the spatial genomics landscape," said Terry Lo, CEO, Vizgen, Inc. "It is another patent underscoring Vizgen’s leadership in the field, providing the industry’s best tools for single-cell spatial biology, and driving discoveries aimed at improving human health," he said

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc. the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today unveiled the MERSCOPE® Ultra Platform and MERFISH 2.0 chemistry at the AACR 2024 Annual Meeting. These powerful tools are uniquely suited to supporting basic and translational research and will be commercially available in the second half of the year. The MERSCOPE Ultra Platform is a powerful new high plex in situ spatial multiomic analysis system. MERSCOPE Ultra features the optimum combined capabilities of imaging area and throughput in a spatial transcriptomics imaging platform. The platform is capable of processing 3 cm2 of tissue on a single slide and acquires images at more than double the speed of the MERSCOPE Platform

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, is very pleased to announce that, on March 7, 2024, the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) denied 10x Genomics Inc.’s petition to institute an Inter Partes Review proceeding (IPR) against U.S. Patent 11,098,303 B2 (‘303 Patent), which Vizgen licenses exclusively from Harvard University. This is the latest in a series of rulings against 10x in its aggressive attempts to weaponize patents to dominate the field through baseless litigation. In its decision denying the institution of an IPR of the ‘303 Patent, the PTAB noted that 10x’s petition was deficient under the law and did not demonstrate “a reasonable likelihood that [10x] would prevail with respect to at least 1 of the claims challenged in the petition.” The denial of petition IPR2023-01299, which is available here, represents a crucial win for Vizgen. In C.A. No